|
Monday, February 13 — 8:00 AM — Centennial II
Click on the numbers in parentheses to display abstracts.
Section C - GYNECOLOGIC PATHOLOGY
Chaired by: Jaime Prat and Brigitte M. Ronnett
| 8:00 |
Stromal Signatures In Ovarian Serous Tumors Of Low Malignant Potential And Serous Carcinomas
(934)
RB West, CB Gilks, M van de Rijn, TA Longacre - Stanford University Medical Center, Stanford, CA; British Columbia Cancer Agency, Vancouver, BC, Canada
|
| 8:15 |
Serous Borderline Tumors With Peritoneal Implants: Clonal Analysis Favors A Monoclonal Origin
(911)
NLG Sieben, GMJM Roemen, J Oosting, GJ Fleuren, Mv Engeland, J Prat - University of Maastricht, Maastricht, Netherlands; Leiden University Medical Centre, Leiden, Netherlands; Hospital Sant Pau, Autonomous University, Barcelona, Spain
|
| 8:30 |
Molecular Genetic of Independent Origin of Serous Low Malignant Potential Implants and Lymph Node Inclusions in Patients with Ovarian Serous Tumors of Low Malignant Potential
(818)
RE Emerson, M Wang, F Liu, WD Lawrence, F Abdul-Karim, L Cheng - Indiana University School of Medicine, Indianapolis, IN; Women & Infants Hospital and Brown Medical School, Providence, RI; Case Western Reserve University, Cleveland, OH
|
| 8:45 |
Coexisting Tubal Intraepithelial Carcinoma (TIC) and Ovarian Serous Carcinoma: Frequency and Implications for the Fallopian Tube as a Source of "Ovarian" Serous Neoplasia.
(853)
DW Kindelberger, Y Lee, C Feltmate, M Callahan, E Garner, RS Berkowitz, MG Muto, CP Crum - Brigham and Women's Hospital, Boston, MA
|
| 9:00 |
Epigenetic Alteration of RASSF1a Distinguishes High Grade from Low Grade Ovarian Serous Carcinoma
(931)
L Wang, P Hui, W Liu, X Zhang, WR Hart, B Yang - Cleveland Clinic Foundation, Cleveland, OH; Yale University, New Haven, CT; Case Western Reserve University, Cleveland, OH
|
| 9:15 |
Invasive Implants of Serous Borderline Ovarian Neoplasms - A Multiinstitutional Study
(914)
E Silva, R Vang, R Kurman, R Soslow, J Prat, T Longacre - MD Anderson Cancer Center, Houston, TX; Armed Forces Institute of Pathology, Washington, DC; The Johns-Hopkins Hospital, Baltimore, MD; Memorial Sloan-Kettering Cancer Center, New York, NY; Hospital de la Santa Crei Sant Pau Autonomous, University of Barcelona, Barcelona, Spain; Stanford University, Stanford, CA
|
| 9:30 |
RECESS, EXHIBITS, POSTER SESSION I
|
| 11:00 |
p16 Expression In Primary Ovarian Mucinous And Endometrioid Tumors And Metastatic Adenocarcinomas In The Ovary: Utility For Identification Of Metastatic HPV-Related Endocervical Adenocarcinomas
(928)
R Vang, AM Gown, TS Barry, DT Wheeler, K Judson, BM Ronnett - The Johns Hopkins Hospital, Baltimore, MD; PhenoPath Laboratories, Seattle, WA; AFIP, Washington, DC
|
| 11:15 |
Expression Of Mesothelial Markers In Ovarian Cancers: A Tissue Microarray Based Study Of 471 Cases
(841)
DN Ionescu, H Masoudi, S Leung, AM Gown, CB Gilks - Vancouver General Hospital, Vancouver, BC, Canada; PhenoPath, Seattle, WA
|
| 11:30 |
Validation Of Potential Chemoresistance Markers In Ovarian Cancer By IHC
(893)
I Popa, S L'Esperance, M Bachvarova, B Tetu, D Bachvarov - Laval University, Quebec, QC, Canada
|
| 11:45 |
Molecular Profiling Of Primary Versus Recurrent Ovarian Serous Papillary Adenocarcinomas
(856)
A Laios, SA O'Toole, BL Sheppard, NC Gleeson, T D'Arcy, EPJ McGuinness, M Ring, O Sheils, JJ O'Leary - Trinity College Dublin and Coombe Women's Hospital, Dublin, Ireland
|
|
|
